Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Celldex Therapeutics, Inc.CLDX · Entity 4208 | SVP, CHIEF MEDICAL OFFICER | June 25, 2026 | June 29, 2026 |
| Oncternal Therapeutics, Inc.GTXI · Entity 89585 | VP, Chief Medical Officer | July 13, 2018 | July 17, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Celldex Therapeutics, Inc.
Report date June 25, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.09 · Expires 2036-06-25 | Direct | 57,000 |
Reported balance
After 2026-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-25 · Grant · Acquired 57,000 · Balance 57,000 F1: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2: 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.
F2: 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
Oncternal Therapeutics, Inc.
Report date July 13, 2018 · Filed July 17, 2018 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 45,936 |
Last balance in matching sequence
After 2018-07-16 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2018-07-13 · Tax withholding · Disposed 2,014 · Balance 47,985 F1: Shares withheld by the issuer pursuant to the Rule 16b-3(c) exemption to satisfy tax withholding obligations arising out of the vesting of a portion of previously granted restricted stock units. Row 2 · 2018-07-16 · Sale · Disposed 2,049 · Balance 45,936 F2: Shares sold to satisfy tax withholding obligations arising out of the vesting of a portion of previously granted restricted stock units. F4: Due to clerical error, the Reporting Person is filing this amendment to correctly indicate the securities were disposed of rather than acquired as was shown in the previous filing on July 17, 2018. The amount of securities beneficially owned following the reported transaction in Table I, Box 5 remains correct. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.43 to $14.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld by the issuer pursuant to the Rule 16b-3(c) exemption to satisfy tax withholding obligations arising out of the vesting of a portion of previously granted restricted stock units.
F2: Shares sold to satisfy tax withholding obligations arising out of the vesting of a portion of previously granted restricted stock units.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.43 to $14.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.
F4: Due to clerical error, the Reporting Person is filing this amendment to correctly indicate the securities were disposed of rather than acquired as was shown in the previous filing on July 17, 2018. The amount of securities beneficially owned following the reported transaction in Table I, Box 5 remains correct.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 25, 2026 Filed Jun 29, 2026 20:20 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantIncentive Stock Option (right to buy) · Derivative | 57,000 | $0.00 Strike: $34.09 | $0.00 |
DisclosureSEC source: 0001648010-26-000002 · form4-06292026_080627.xml · derivative · entry 1 Young Diane C. · CIK 0001648010 · SVP, CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,000 Underlying: Common Stock · 57,000 shares Expires 2036-06-25 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:15 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantIncentive Stock Option (right to buy) · Derivative | 72,000 | $0.00 Strike: $19.53 | $0.00 |
DisclosureSEC source: 0001415889-25-016238 · form4-06092025_080613.xml · derivative · entry 1 Young Diane C. · CIK 0001648010 · SVP, CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,000 Underlying: Common Stock · 72,000 shares Expires 2035-06-05 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 5, 2026 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:18 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantIncentive Stock Option (right to buy) · Derivative | 72,000 | $0.00 Strike: $36.43 | $0.00 |
DisclosureSEC source: 0001415889-24-017186 · form4-06172024_080635.xml · derivative · entry 1 Young Diane C. · CIK 0001648010 · SVP, CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,000 Underlying: Common Stock · 72,000 shares Expires 2034-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 13, 2025 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 20:05 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | Exercise / conversionIncentive Stock Option · Derivative | 15,000 | $0.00 Strike: $2.71 | $0.00 |
DisclosureSEC source: 0001415889-24-016651 · form4-06132024_080617.xml · derivative · entry 2 Young Diane C. · CIK 0001648010 · SVP, CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2029-07-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: As of July 8, 2023, the option is fully vested. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 20:05 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | Exercise / conversionCommon Stock | 15,000 | $2.71 | $40,650.00 |
DisclosureSEC source: 0001415889-24-016651 · form4-06132024_080617.xml · nonDerivative · entry 1 Young Diane C. · CIK 0001648010 · SVP, CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,115 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 20:01 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | SaleCommon Stock | 45,000 | $35.26 | $1,586,844.00 |
DisclosureSEC source: 0001415889-24-016344 · form4-06112024_080650.xml · nonDerivative · entry 1 Young Diane C. · CIK 0001648010 · SVP, CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,115 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.67 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 20:21 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantIncentive Stock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $36.87 | $0.00 |
DisclosureSEC source: 0001415889-23-010049 · form4-06202023_080658.xml · derivative · entry 1 Young Diane C. · CIK 0001648010 · SVP, CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2033-06-15 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 15, 2024 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:05 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | Exercise / conversionIncentive Stock Option · Derivative | 45,000 | $0.00 Strike: $2.71 | $0.00 |
DisclosureSEC source: 0001415889-22-008895 · form4-08192022_010835.xml · derivative · entry 5 Young Diane C. · CIK 0001648010 · SVP, CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 45,000 shares Expires 2029-07-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% vested on July 8, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:05 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | Exercise / conversionIncentive Stock Option · Derivative | 19,000 | $0.00 Strike: $10.38 | $0.00 |
DisclosureSEC source: 0001415889-22-008895 · form4-08192022_010835.xml · derivative · entry 4 Young Diane C. · CIK 0001648010 · SVP, CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,400 Underlying: Common Stock · 19,000 shares Expires 2030-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:05 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | Exercise / conversionCommon Stock | 45,000 | $2.71 | $121,950.00 |
DisclosureSEC source: 0001415889-22-008895 · form4-08192022_010835.xml · nonDerivative · entry 3 Young Diane C. · CIK 0001648010 · SVP, CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,115 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:05 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | SaleCommon Stock | 19,000 | $37.30 | $708,715.20 |
DisclosureSEC source: 0001415889-22-008895 · form4-08192022_010835.xml · nonDerivative · entry 2 Young Diane C. · CIK 0001648010 · SVP, CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,115 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.30 to $37.35 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:05 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | Exercise / conversionCommon Stock | 19,000 | $10.38 | $197,220.00 |
DisclosureSEC source: 0001415889-22-008895 · form4-08192022_010835.xml · nonDerivative · entry 1 Young Diane C. · CIK 0001648010 · SVP, CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,115 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 20:15 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantIncentive Stock Option (right to buy) · Derivative | 76,000 | $0.00 Strike: $22.48 | $0.00 |
DisclosureSEC source: 0001415889-22-006726 · form4-06172022_010610.xml · derivative · entry 1 Young Diane C. · CIK 0001648010 · SVP, CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,000 Underlying: Common Stock · 76,000 shares Expires 2032-06-16 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 16, 2023 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 21:02 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 4,600 | $0.00 Strike: $10.38 | $0.00 |
DisclosureSEC source: 0001179110-21-010165 · edgar.xml · derivative · entry 3 Young Diane C. · CIK 0001648010 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,400 Underlying: Common Stock · 4,600 shares Expires 2030-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 21:02 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | SaleCommon Stock | 4,600 | $42.94 | $197,529.06 |
DisclosureSEC source: 0001179110-21-010165 · edgar.xml · nonDerivative · entry 2 Young Diane C. · CIK 0001648010 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,115 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.6400 to $43.2000 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 21:02 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | Exercise / conversionCommon Stock | 4,600 | $10.38 | $47,748.00 |
DisclosureSEC source: 0001179110-21-010165 · edgar.xml · nonDerivative · entry 1 Young Diane C. · CIK 0001648010 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,715 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:29 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantIncentive Stock Option (right to buy) · Derivative | 72,000 | $0.00 Strike: $28.00 | $0.00 |
DisclosureSEC source: 0001179110-21-006911 · edgar.xml · derivative · entry 1 Young Diane C. · CIK 0001648010 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,000 Underlying: Common Stock · 72,000 shares Expires 2031-06-17 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 17, 2022 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 12:05 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantIncentive Stock Option (right to buy) · Derivative | 72,000 | $0.00 Strike: $10.38 | $0.00 |
DisclosureSEC source: 0001179110-20-007592 · edgar.xml · derivative · entry 1 Young Diane C. · CIK 0001648010 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,000 Underlying: Common Stock · 72,000 shares Expires 2030-06-18 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 11, 2020 Filed Jun 12, 2020 11:55 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | PurchaseCommon stock, par value $0.001 per share | 2,115 | $4.73 | $10,003.95 |
DisclosureSEC source: 0001179110-20-007242 · edgar.xml · nonDerivative · entry 1 Young Diane C. · CIK 0001648010 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,115 Read SEC document |
| July 08, 2019 Filed Jul 9, 2019 12:18 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantIncentive Stock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $2.71 | $0.00 |
DisclosureSEC source: 0001179110-19-008540 · edgar.xml · derivative · entry 1 Young Diane C. · CIK 0001648010 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-07-08 F1 · security: Represents option granted by Issuer pursuant to its 2008 Stock Option and Incentive Plan. F2 · derivative.exercise_date: 25% vests on July 8, 2020 and the remainder vests quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| July 16, 2018 Filed Jul 17, 2018 17:49 UTC Amendment | Oncternal Therapeutics, Inc. GTXI · Entity 89585 | SaleCommon Stock | 2,049 | $14.70 | $30,120.30 |
DisclosureSEC source: 0001179110-18-009767 · edgar.xml · nonDerivative · entry 2 Young Diane C. · CIK 0001648010 · VP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,936 F2 · kind: Shares sold to satisfy tax withholding obligations arising out of the vesting of a portion of previously granted restricted stock units. F4 · shares: Due to clerical error, the Reporting Person is filing this amendment to correctly indicate the securities were disposed of rather than acquired as was shown in the previous filing on July 17, 2018. The amount of securities beneficially owned following the reported transaction in Table I, Box 5 remains correct. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.43 to $14.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4. Read SEC document |
| July 16, 2018 Filed Jul 17, 2018 17:03 UTC | Oncternal Therapeutics, Inc. GTXI · Entity 89585 | SaleCommon Stock | 2,049 | $14.70 | $30,120.30 |
DisclosureSEC source: 0001179110-18-009758 · edgar.xml · nonDerivative · entry 2 Young Diane C. · CIK 0001648010 · VP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,936 F2 · kind: Shares sold to satisfy tax withholding obligations arising out of the vesting of a portion of previously granted restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.43 to $14.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4. Read SEC document |
| July 13, 2018 Filed Jul 17, 2018 17:49 UTC Amendment | Oncternal Therapeutics, Inc. GTXI · Entity 89585 | Tax withholdingCommon Stock | 2,014 | $14.92 | $30,048.88 |
DisclosureSEC source: 0001179110-18-009767 · edgar.xml · nonDerivative · entry 1 Young Diane C. · CIK 0001648010 · VP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,985 F1 · kind: Shares withheld by the issuer pursuant to the Rule 16b-3(c) exemption to satisfy tax withholding obligations arising out of the vesting of a portion of previously granted restricted stock units. Read SEC document |
| July 13, 2018 Filed Jul 17, 2018 17:03 UTC | Oncternal Therapeutics, Inc. GTXI · Entity 89585 | Tax withholdingCommon Stock | 2,014 | $14.92 | $30,048.88 |
DisclosureSEC source: 0001179110-18-009758 · edgar.xml · nonDerivative · entry 1 Young Diane C. · CIK 0001648010 · VP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,985 F1 · kind: Shares withheld by the issuer pursuant to the Rule 16b-3(c) exemption to satisfy tax withholding obligations arising out of the vesting of a portion of previously granted restricted stock units. Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 18:25 UTC | Oncternal Therapeutics, Inc. GTXI · Entity 89585 | GrantEmployee Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $12.71 | $0.00 |
DisclosureSEC source: 0001179110-18-000406 · edgar.xml · derivative · entry 1 Young Diane C. · CIK 0001648010 · VP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-12-31 F1 · derivative.exercise_date: The option vests and is exercisable in 3 equal annual installments beginning January 1, 2021. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 16:57 UTC | Oncternal Therapeutics, Inc. GTXI · Entity 89585 | GrantEmployee Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $4.71 | $0.00 |
DisclosureSEC source: 0001179110-17-003652 · edgar.xml · derivative · entry 1 Young Diane C. · CIK 0001648010 · VP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-02-27 F1 · derivative.exercise_date: The option vests and is exercisable in 3 equal annual installments beginning February 28, 2020. Read SEC document |
| October 28, 2016 Filed Feb 28, 2017 17:16 UTC | Oncternal Therapeutics, Inc. GTXI · Entity 89585 | SaleCommon Stock | 500 | $7.70 | $3,850.00 |
DisclosureSEC source: 0001179110-17-003389 · edgar.xml · nonDerivative · entry 1 Young Diane C. · CIK 0001648010 · VP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 0 F1 · shares: On December 5, 2016, the Issuer effected a one-for-ten reverse stock split of its Common Stock (the "Reverse Split"). The number of shares and sale price per share as shown in the table above has been adjusted to reflect the Reverse Split. F1 · price: On December 5, 2016, the Issuer effected a one-for-ten reverse stock split of its Common Stock (the "Reverse Split"). The number of shares and sale price per share as shown in the table above has been adjusted to reflect the Reverse Split. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.